Pieter Van der Veken, Achiel Haemers and Koen Augustyns Pages 621 - 635 ( 15 )
Dipeptidyl peptidase IV (DPP IV) is a validated target for the treatment of type 2 diabetes, with several inhibitors currently in phase 3 clinical trials. This review will mainly focus on proline-specific dipeptidyl peptidases related to DPP IV: fibroblast activation protein (FAP), dipeptidyl peptidase 8 (DPP8), dipeptidyl peptidase 9 (DPP9) and dipeptidyl peptidase II (DPP II). The biochemical and biological properties of these enzymes will be discussed, as well as the therapeutic potential of their inhibition. The development of potent and selective inhibitors for each of these peptidases will be described.
Dipeptidyl peptidase, DPP IV, DPP II, DPP8, DPP9, FAP, medicinal chemistry
Department of Medicinal Chemistry, University of Antwerp, Universiteitsplein 1, B-2610 Antwerpen,Belgium.